Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Europe The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet its ability to translate scientific excellence into timely and equitable patient access is becoming the defining challenge for the region’s…
USA Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining in January. With an ambition to build a 1 billion USD global business (the US is expected to drive more…
Germany Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its healthcare and industrial priorities, the decisions taken today will shape the sector’s competitiveness for decades to come. Dr Kai Joachimsen,…
Germany Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the rare disease challenge in Germany. Despite being one of Europe’s most advanced pharmaceutical markets, patients still face long diagnostic journeys…
Germany Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right policy environment, sustained investment, and a shared commitment to innovation. Daniel Steiners discusses how Roche is strengthening its position across…
Korea But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on Korea’s transformation into a global oncology research hub, highlighting the impact of the K-MASTER precision medicine initiative, advances in cancer…
Korea Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines Korea’s transition from a generics-driven industry to a global innovation hub. He highlights the government’s strategic support, a growing pipeline…
Korea If you concentrate on shared goals, collaboration and a unified voice follow naturally. Youngshin Lee, CEO of KRPIA, has built a career spanning more than three decades across pharmaceutical R&D, industry, and policy, advocating for collaboration between regulators, industry, and patients. Under her leadership, KRPIA has become a key voice…
USA Randy Teel, President and CEO of Arvinas, outlines the company’s evolution from a Yale-founded research platform into a leader in targeted protein degradation. He explains how Arvinas is working to develop potential new therapies using PROTAC technology that harnesses the body’s natural protein disposal system to destroy disease-causing proteins, with…
Korea Dr Jeongseok Lee has served as President of the Korea Biomedicine Industry Association (KoBIA) since September 2020, backed by an outstanding 35-year career in public service and longstanding leadership in the healthcare sector. During a period marked by the unprecedented public health crisis of the COVID-19 pandemic and the significant…
See our Cookie Privacy Policy Here
